JEFFREY MANDL: Open Payments
NPI 1518234384 · BROOMFIELD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$543 in 26 payments from 14 companies in 2025. Trend: 2023 $267 · 2024 $361 · 2025 $543
Food & beverage: $543
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $96 |
| GlaxoSmithKline, LLC. | 4 | $84 |
| ABBVIE INC. | 3 | $54 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| Lilly USA, LLC | 2 | $46 |
| Merck Sharp & Dohme LLC | 2 | $38 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $32 |
| ABIOMED | 1 | $26 |
| Dexcom, Inc. | 1 | $26 |
| Organon LLC | 1 | $21 |
Products named: AREXVY, KRYSTEXXA, ZEPBOUND, NEXIUM, QULIPTA, Kerendia, Dexcom G6 Transmitter, UBRELVY.
Industry payments across CO — which companies pay providers there.
